CN Patent
CN113286584A — 治疗骨髓增生性病症的方法
Assigned to Impact Biomedicines Inc · Expires 2021-08-20 · 5y expired
What this patent protects
本公开提供了缓和硫胺素缺乏症的方法。
USPTO Abstract
本公开提供了缓和硫胺素缺乏症的方法。
Drugs covered by this patent
- Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.